Clinical Trial Update: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial of talquetamab in participants with relapsed or refractory multiple myeloma that is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Talquetamab (talquetamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hematological Malignancies | Phase 2 | Status: RECRUITING